Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Apr 21;78:103944. doi: 10.1016/j.ebiom.2022.103944

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2022 The Authors. Published by Elsevier B.V.

This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

PMC Copyright notice

Fig 2 — Therapeutic monoclonal antibodies have lost neutralizing activity against virus with the Omicron spike protein.

a. Neutralization of viruses with the VOC spike proteins by Regeneron REGN10933 (Casirivamab) and REGN10987 (Imdevimab) monoclonal antibodies and the REGN-CoV-2 cocktail was measured using spike variant spike protein-pseudotyped viruses.

b. Neutralization of viruses pseudotyped by the VOC spike proteins by LY-CoV555 (Bamlanivimab), LY-CoV016 (Etesevimab) monoclonal antibodies and cocktail were measured as in a above.

c. Neutralization of viruses, pseudotyped by the VOC spike proteins, by AZD8895 (Tixagevimab), AZD1061 (Cilgavimab) and combination Evusheld.

d. Neutralization of viruses pseudotyped by the VOC spike proteins by VIR-7831 (Sotrovimab) was measured as in a above.

e. The table shows the IC50s of the therapeutic monoclonal antibodies calculated using the data from the antibody neutralization curves shown in a, b and c. Larger numbers indicate decreased neutralization potency. Antibodies that did not reach >70% infectivity at the highest concentration tested are listed as IC50>5000; for antibodies that reached 51–70% infectivity at the highest concentration tested, the IC50 was extrapolated using GraphPad Prism 8 software.